1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
1.55(c) 1.63(c) 1.58(c) 1.65(c) 1.53 Last
8 933 573 5 179 160 3 653 681 5 301 641 4 431 692 Volume
+2.65% +5.16% -3.07% +4.43% -7.27% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 62,2 M - -
Net income 2022 -238 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,71x
Yield 2022 -
Sales 2023 95,8 M - -
Net income 2023 -235 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,01x
Yield 2023 -
Capitalization 415 M 415 M -
Capi. / Sales 2022 6,67x
Capi. / Sales 2023 4,33x
Nbr of Employees 441
Free-Float 89,9%
More Financials
Company
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4... 
More about the company
Ratings of Agenus Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about AGENUS INC.
05/12TARGOVAX ASA : First quarter 2022 results
AQ
05/11Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 me..
AQ
05/11Targovax Announces Clinical Collaboration with Agenus for Upcoming ONCOS-102 Phase 2 Me..
CI
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/10TRANSCRIPT : Agenus Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10AGENUS : Q1 Earnings Snapshot
AQ
05/10Agenus Corporate Update and First Quarter 2022 Financial Report
GL
05/10Agenus Corporate Update and First Quarter 2022 Financial Report
AQ
05/10AGENUS INC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vacc..
AQ
04/26Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
GL
04/26Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
GL
04/08AGENUS : AACR2022_Udartseva, et al. Poster
PU
04/08Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
GL
More news
News in other languages on AGENUS INC.
05/11L'efficacité du médicament anticancéreux de Roche remise en question
05/11Targovax annonce une collaboration clinique avec Agenus pour le prochain essai de phase..
05/11Aussicht auf neue Roche-Lungenkrebstherapie schwindet
05/10Agenus Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/08Agenus Inc. Présente des données sur l'AGEN1571 (anti-ILT2) à l'AACR et annonce l'appro..
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | AGEN | US00847G7051 | MarketScreener
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,53 $
Average target price 9,67 $
Spread / Average Target 532%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Steven OĺDay Chief Medical Officer
Craig Winter Chief Information Officer
Wadih Jordan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.-48.76%447
MODERNA, INC.-45.78%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-30.08%39 122
SEAGEN INC.-7.50%26 976
ICON PUBLIC LIMITED COMPANY-34.37%17 002